🚀 More #irAE highlights forthcoming from #ASCO25 and ASCO’s #ASPIRE Community of Practice
🆕 go-to hub for clinicians addressing immune-related toxicities!
🌟 FREE access for non-oncologists (for a limited time), expert discussion + content
https://t.co/3C2Fm3cYyr
Thank you OncoDaily! Honored to be on the ballot for the 2025 @IASLC Board of Directors and look forward to the opportunity to expand optimal lung cancer care and clinical trials on a global scale. @RamalingamMD@IASLC@WinshipAtEmory
Its a wrap!
It was a pleasure to host my colleagues and friends around the country for the 2nd #ASPIRE2025 and 3rd #NICT2025 meeting
25 speakers
38 organizations
15 specialties
One place @DukeCancer@DukeCancerNETWK
One mission- #irAE
It’s a wrap for ASPirE ‘25! In medicine we continually see new challenges, face deadly obstacles, and wake up the next day to do it again. Sometimes in light. Sometimes dark. We give each other strength. Keep going fam. Keep going dear patients. Medicine perseveres. Love, ASPirE
Check out poster board E23 🇧🇷 at #GU25@ASCO
We evaluated the incidence of skin reaction in EV mono in clinical trials and real-world data
📊 Incidence rate of all-grade skin reactions was 50% and about 10% in grade 3 or higher
@MaysaVilbert@isabfmichelon@anacardosomd
New in Cancer Treatment Reviews!
This updated meta-analysis continues to support the activity of T-DXd in patients with CNS involvement from HER2-positive #breastcancer.
@LudiCa19862@MaysaVilbert@AnwaarSaeed3
🔗https://t.co/S4mLPRWZVj
Top of the irAE to you this Monday! 2 ASPirE events to kick off 2025:
ASPirE Annual Meeting 2/28 - 3/1: in person think tank graciously hosted by @afreenshariffmd@dukemedicine
ASPirE Webinar 3/10: Launch of our Tumor Board series hosted by Yinghong Mimi Wang @MDAndersonNews
From Rio de Janeiro to Boston, Cardiff to Kaliningrad, Recife to Madrid – this publication is a testament to the global connections made possible by the #metamasters.
Yasmin Mesquita led a study published in the prestigious ‘Journal of the European Academy of Dermatology and Venereology’. Her analysis of nine studies highlighted confocal microscopy as a viable alternative to histopathology in #melanoma margin mapping.
Always an inspiration to hear Dr Stephanie Goff present on #TILs. We need to stop thinking about this as palliative therapy! TILs have the potential to CURE- complete responders from @theNCI with 10 year melanoma-specific survival of 96%. Unmodified TILs are just a starting point. Now, how do get MORE of our patients to a CR? #ImmunotherapyBridge24
Safety and Efficacy of Osimertinib in Patients With NSCLC and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. https://t.co/taHeJNM4bp @thenasheffect#LungCancer#NSCLC
1/ I’m thrilled to share our study, “Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies,” now published in @JCOGO_ASCO !
🔗 https://t.co/rgJeQmjqUU
This study reflects the dedication and teamwork of everyone involved.
So proud to share our work in @JCOPO_ASCO
🫁Our meta-analysis highlights the safety and efficacy of #osimertinib in patients with #NSCLC and uncommon #EGFR mutations. I’m really glad and honored to have this amazing international collaboration with this dream team.
Proud to share our work in @TAMedOncol!
Our meta-analysis of 2000+ patients with #HER2-low #MBC reveals a 50% reduction in the risk of progression/death with ADCs compared to chemo.
#BCSM
🔗 full: https://t.co/Cl4MssJIv6